Schoeps Megan 4
4 · Bellerophon Therapeutics, Inc. · Filed Dec 13, 2017
Insider Transaction Report
Form 4
Schoeps Megan
Principal Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2017-12-13$0.49/sh+1,000$490→ 19,248 total - Exercise/Conversion
Stock Option (right to buy)
2017-12-13−1,000→ 3,000 totalExercise: $0.49Exp: 2026-12-07→ Common Stock (1,000 underlying)
Footnotes (1)
- [F1]This option vests as to 25% of the underlying shares on each one year anniversary of the date of grant.